Novavax, Inc. (NVAX) News
Follow Novavax, Inc. (NVAX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 33 public stories across 18 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Novavax Reports Q3 Revenue of $68.3 Million, Raises 2026 Guidance
Novavax reported a $31.4 million net loss, down 85% year over year, and raised its full-year 2026 non-GAAP adjusted total revenue guidance by $145 million to a $400 million midpoint. The increase includes a $125 million
EQUITY | Nov 05, 2026, 10:32 PM UTC
L
PUNTO 3-Novavax posticipa l'obiettivo di redditività al 2029, azioni calano
PUNTO 3-Novavax posticipa l'obiettivo di redditività al 2029, azioni calano Novavax prevedeva di rag
EQUITY | Nov 05, 2026, 04:33 PM UTC
L
ACTUALIZA 3-Novavax retrasa su objetivo de rentabilidad hasta 2029; las acciones caen
ACTUALIZA 3-Novavax retrasa su objetivo de rentabilidad hasta 2029; las acciones caen Novavax espera
EQUITY | Nov 05, 2026, 04:33 PM UTC
L
LEAD 3-Novavax repousse son objectif de rentabilité à 2029, le titre recule
LEAD 3-Novavax repousse son objectif de rentabilité à 2029, le titre recule Novavax prévoyait d'atte
EQUITY | Nov 05, 2026, 04:33 PM UTC
M
Novavax Pushes Profitability Target to 2029
Novavax pushed its profitability target to 2029. Its shares dipped.
EARNINGS | Nov 05, 2026, 04:33 PM UTC
M
Novavax Raises FY26 Revenue Outlook by More Than 50%
Novavax raised its full-year 2026 adjusted revenue outlook by more than 50% at the upper end, supported by growing revenue opportunities from vaccine licensing partnerships.
EARNINGS | Nov 05, 2026, 03:38 PM UTC
M
Novavax Raises 2026 Revenue Forecast
Novavax raised its 2026 revenue forecast, citing expected licensing deals.
EARNINGS | Nov 05, 2026, 02:55 PM UTC
M
Novavax Reports Q3 Loss of $0.19 a Share, Below FactSet Estimate
Novavax posted a Q3 net loss of $0.19 per share, compared with FactSet's $0.35 loss estimate.
EQUITY | Nov 05, 2026, 01:31 PM UTC
M
Novavax Reports Q3 2026 Revenue of $68 Million
Novavax reported $68 million in revenue for the third quarter of 2026. The body says the company raised its full-year 2026 non-GAAP outlook, but the figure is truncated.
EQUITY | Nov 05, 2026, 01:06 PM UTC
M
Novavax Earns $125 Million Milestone Payment From Sanofi Vaccine Trial
Novavax earned a $125 million milestone payment from Sanofi's Phase 3 vaccine trial in Europe.
EQUITY | Oct 29, 2026, 02:38 PM UTC
L
Novavax Eligible for Royalties and $75 Million Milestone Payment
Novavax is eligible for royalties and a $75 million milestone payment on a technology transfer in mid-2027.
EQUITY | Oct 29, 2026, 01:41 PM UTC
M
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Trial
Sanofi launched a Phase 3 trial in Europe of its influenza-COVID-19 combination vaccine. Novavax earned a $125 million milestone.
EQUITY | Oct 29, 2026, 01:41 PM UTC
H
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
Author Stephen King has criticized President Donald Trump’s new White House press secretary, Katie Zacharia, over her past social media posts promoting vaccine-related claims, questioning the 2020 election results and al
LIVE | Oct 12, 2026, 09:12 AM UTC
H
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
A nationwide initiative to accelerate personalized cancer vaccine development is drawing fresh investor interest in vaccine makers, sending several biotechnology and pharmaceutical stocks higher Friday. Moderna, Inc. (NA
LIVE | Oct 09, 2026, 07:11 PM UTC
H
Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Friday. Shares of Humana Inc (NYSE: HUM ) rose sharply after the company said Friday that its 2027 Medicare Advantage Star Ratings improved
LIVE | Oct 09, 2026, 02:51 PM UTC
H
Transcript: Novavax Q2 2026 Earnings Conference Call
Novavax (NASDAQ: NVAX ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings call transc
LIVE | Oct 07, 2026, 10:50 AM UTC
M
Vaccine Stocks Rally on Speculation of Contract Awards After Russia Lab Incident
Novavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS) and Arcturus Therapeutics (ARCT) advanced after a death at a Russian plague research institute. Retail investors speculated about potential federal contract awa
EQUITY | Oct 06, 2026, 03:34 AM UTC
M
Novavax Shares Surge 20% After Rival's Strong Trial Data Boosts Vaccine Stocks
Novavax Inc. (NVAX) shares experienced their best trading session since January, jumping 20% on Monday. This surge was attributed to a competitor's positive late-stage trial results for a vaccine, which broadly lifted va
EQUITY | Oct 05, 2026, 11:42 PM UTC
L
NVAX: Strategic shift to licensing and Matrix-M partnerships drives growth in vaccines and oncology
A major strategic pivot has shifted focus to licensing and partnerships, with Matrix-M technology now central to both infectious disease and oncology pipelines. Key alliances with top pharma, strong financial milestones,
EQUITY | Sep 09, 2026, 08:11 PM UTC
L
NVAX: Major pharma partnerships, Matrix-M expansion, and global commercialization drive future growth
The company shifted from a single-product focus to global technology licensing, securing major pharma partnerships and reducing costs. Matrix-M is used in infectious disease and oncology, with new data expected. Global c
EQUITY | Sep 09, 2026, 07:37 PM UTC
L
NVAX - Novavax to Participate in September Investor Conferences
NVAX - Novavax to Participate in September Investor Conferences
EQUITY | Sep 02, 2026, 09:00 PM UTC
L
Novavax management to participate in September investor conferences
Novavax said management will participate in upcoming September investor conferences. Live webcasts of the fireside chats will be available on the company’s “Events & Presentations” page.
EQUITY | Sep 02, 2026, 09:00 PM UTC
L
Novavax shares rise after FDA authorization and guidance upgrade
Novavax shares are trading higher Tuesday after U.S. FDA emergency use authorization for its updated 2026-2027 Nuvaxovid vaccine and an earlier Q2 update that raised full-year revenue guidance.
EARNINGS | Sep 01, 2026, 04:47 PM UTC
L
NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open
NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open
EQUITY | Aug 28, 2026, 10:35 PM UTC
L
NVAX - Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vac
NVAX - Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
EQUITY | Aug 28, 2026, 12:30 PM UTC
M
US FDA approves updated COVID vaccines for 2026-27 season
US FDA approves updated COVID vaccines for the 2026-27 season.
REGULATION | Aug 27, 2026, 09:41 PM UTC
L
Novavax shares rise after Q2 revenue beat, 2026 guidance lift
Novavax says Q2 revenue of $56.7 million topped Wall Street consensus and it raised full-year 2026 revenue guidance to $235 million-$275 million, supporting a late-morning stock gain.
EARNINGS | Aug 25, 2026, 03:31 PM UTC
H
Novavax rises as biotech rally spreads after Merck-Moderna data
Novavax shares are trading higher Wednesday as a broad biotech rally follows Merck and Moderna Phase 3 INTerpath-001 melanoma results; no Novavax-specific catalyst was supplied.
EQUITY | Aug 19, 2026, 04:33 PM UTC
H
US President Signs Order On Childhood Vaccines
US President signs executive order on childhood vaccines
REGULATION | Aug 10, 2026, 05:50 PM UTC
L
Novavax Raises FY2026 Sales Guidance from $230.000M-$270.000M to $235.000M-$275.000M vs $389.234M Est
Novavax (NASDAQ: NVAX ) raises FY2026 sales outlook from $230.000 million-$270.000 million to $235.000 million-$275.000 million vs $389.234 million estimate.
EARNINGS | Aug 06, 2026, 12:02 PM UTC
L
NVAX NVAX - Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights
NVAX NVAX - Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights
EARNINGS | Aug 06, 2026, 12:00 PM UTC
L
NVAX NVAX - Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
NVAX NVAX - Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
EARNINGS | Jul 30, 2026, 11:00 AM UTC
H
Novavax put volume heavy and directionally bearish
Bearish flow noted in Novavax with 2,130 puts trading, or 4x expected. Most active are Jul-26 8 puts and 7/31 weekly 8 puts, with total volume in those strikes near 1,500 contracts. The Put/Call Ratio is 2.14, while ATM
EQUITY | Jul 10, 2026, 03:15 PM UTC